ALPS Medical Breakthroughs ETF

SBIO is a US Equities ETF. The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the "Underlying Index"). The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States and in the stocks of companies operating in the biotechnology sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the S-Network Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.

SBIO tracks the S-Network Medical Breakthroughs Index.

No, SBIO is not actively managed. It is passively managed. In an actively managed fund, the fund manager makes decisions about how funds are invested. A passively managed fund typically tries to track or follow a market index.

Yes, SBIO is passively managed. A passively managed fund typically tries to track or follow a market index. In an actively managed fund, the fund manager makes decisions about how funds are invested.

The 1-month return on SBIO is -0.0842%. This is the percent change in the value of SBIO over the most recent 1-month period. The 3-month return on SBIO is -0.146%. This is the percent change in the value of SBIO over the most recent 3-month period.

The standard deviation of SBIO for the past year is 0.2934%. Standard deviation is the typical amount that the daily returns vary from the mean of the returns over the time period, standardized to a period of a year.

ETFs similar to SBIO include XLI, XLY, and XLV.

ETFs correlated to SBIO include LABU, XBI, and GNOM.

ETFs that are inversely correlated to SBIO include LABD, SRTY, and TZA.